Understanding Post-Menopausal Vaginal Discomfort
Post-menopausal vulvovaginal disorders are an extremely common yet often overlooked condition, affecting approximately 50% of women. Symptoms such as dryness, itching, burning, pain during intercourse, and general daily discomfort not only compromise quality of life but also impact psychological well-being and interpersonal relationships.
In this context, Revaginal Gel stands out as an effective treatment for alleviating post-menopausal vulvovaginal discomfort, as confirmed by the results of our recent clinical study.
Study Objective: Measuring Revaginal Gel’s Impact on Intimate Well-being
Promoted by Gruppo FarmaImpresa, the clinical study’s primary objective was to evaluate the efficacy of this medical device. Measurement was conducted using the VSQ (Vulvovaginal Symptoms Questionnaire), a standardized and validated tool specifically designed to quantify the presence and impact of key symptoms like itching, dryness, pain, irritation, and sexual difficulties in post-menopausal patients.
Research Methodology
The research involved 20 patients who completed the VSQ questionnaire in two distinct phases:
- T0: Before starting treatment (baseline symptoms).
- T1: After approximately two weeks of continuous treatment with Revaginal Gel. After just two weeks of treatment, the results showed remarkable improvements across all evaluated parameters.
The following graph illustrates the drastic reduction in perceived symptoms after two weeks of vaginal gel application:
As shown in the graph, the average score decreased from an initial 3.75 to 1.00. This significant reduction in perceived symptoms was statistically confirmed by the paired t-test (p < 0.001), highlighting the extreme relevance and efficacy of the treatment, even within a very short timeframe.
Impact on Emotional and Relational Spheres
The benefits of Revaginal Gel extended far beyond the physical dimension, profoundly impacting emotional and relational aspects:
- “Emotions”: The percentage of patients without emotion-related symptoms rose from 65% to 95%.
- “Impact on daily life”: A similar improvement, increasing from 65% to 95%, demonstrates greater participation and comfort in daily activities.
- “Impact on sexuality”: Significant improvements were observed in crucial parameters such as desire, reduction of pain, dryness, and discomfort during intercourse.
Regular use of the product for just two weeks led to a reduction in symptoms and an improvement in the patients’ quality of life, positively extending to psychological and relational aspects. Revaginal Gel, therefore, represents a valid therapeutic option for women’s intimate well-being during such a delicate phase of their lives, offering not only physical relief but a true recovery of comfort and serenity.
If you are interested in becoming a distributor of our Revaginal Gel, a CE-certified medical device in compliance with the Medical Device Regulation (EU) 2017/745 MDR (Medical Device Regulation), either in private label or out-licensing, we are ready to support you in your growth and provide customised solutions for your market. Our focus on quality and customer satisfaction makes us the ideal partner to expand your healthcare offering.
